IVA Inventiva S.A.

Biotech Analyst Ratings

Latest News

1. 16 May 2022 Inventiva reports 2022 First Quarter Financial Information and provides clinical development update

   • Cash position² at €80.5m as of March 31, 2022
   • The Group did not generate any revenue in Q1 2022
   • Signature of a €50 million bullet credit facility agreement with the European Investment Bank
   • Update on lanifibranor recruitment timing for Phase III trial in patients with NASH, as well as for the two Phase II trials in patients with NAFLD and type 2 diabetes, and in combination with empagliflozine

   Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today reported…

   View Full Article
2. 16 May 2022 Inventiva secures a €50 million credit facility from the European Investment Bank

   • This credit facility is intended to support the progress and expansion of Inventiva's pipeline
   • The credit facility consists of two tranches of €25 million each
   • Credit agreement is part of the European Investment Bank's strategy to support biotech companies developing a high-level of expertise in various therapeutic areas with significant unmet medical needs  

   Daix (France), Long Island City (New York, United States), May 16, 2022 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced the signing of a €50 million…

   View Full Article
3. 07 April 2022 Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver

   Daix (France), Long Island City (New York, United States), April 7, 2022 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that the abstract "Lanifibranor, a pan-PPAR agonist, improves markers of cardiometabolic health in patients with NASH" has been selected for oral presentation during the third International Conference on Fatty Liver to be held from the 28^th to the 30^th of April 2022 in Vienna, Austria.
   

   
    

   This abstract focuses on the improvement of markers of cardiometabolic health in patients with NASH treated with lanifibranor…

   View Full Article
4. 11 March 2022 Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F

   Daix (France), Long Island City (New York, United States), March 11, 2022 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report, with the French "Autorité des Marchés Financiers" (AMF) and its 2021 Annual Report on Form 20-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission (SEC).

   These documents can be accessed on the "Investors" section of the…

   View Full Article
5. 08 March 2022 Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA

   • FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed

   • The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023

   
    

   Daix (France), Long Island City (New York, United States), March 8, 2022 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has completed its safety review of the IND application and has concluded that the proof-of-concept Phase II combination trial with its lead drug candidate lanifibranor…

   View Full Article